Scarica l'app Stockscreener
18.57
1.59%
-0.30
Dopo l'orario di chiusura:
18.55
-0.02
-0.11%
Precedente Chiudi:
$18.87
Aprire:
$19.17
Volume 24 ore:
39,159
Relative Volume:
0.82
Capitalizzazione di mercato:
$864.96M
Reddito:
-
Utile/perdita netta:
$-75.28M
Rapporto P/E:
-9.305
EPS:
-1.9957
Flusso di cassa netto:
$-57.45M
1 W Prestazione:
+3.98%
1M Prestazione:
+19.81%
6M Prestazione:
+5.75%
1 anno Prestazione:
+45.08%
Intervallo 1D:
$18.43
$19.18
Intervallo di 1 settimana:
$17.01
$19.19
Portata 52W:
$10.79
$23.08
Oculis Holding Ag Stock (OCS) Company Profile
Nome
Oculis Holding Ag
Settore
Industria
Telefono
-
Indirizzo
-
Confronta OCS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
18.57 | 864.96M | 0 | -75.28M | -57.45M | -1.9957 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-05 | Iniziato | Chardan Capital Markets | Buy |
| 2023-10-05 | Iniziato | Stifel | Buy |
| 2023-06-14 | Iniziato | BofA Securities | Buy |
| 2023-06-12 | Iniziato | H.C. Wainwright | Buy |
| 2023-06-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-05-10 | Iniziato | Pareto | Buy |
| 2023-04-28 | Iniziato | Wedbush | Outperform |
Mostra tutto
Oculis Holding Ag Borsa (OCS) Ultime notizie
Oculis (NASDAQ:OCS) Sees Unusually-High Trading Volume – Still a Buy? - Defense World
Oculis Holding AG (NASDAQ:OCS) Shares Bought by Geode Capital Management LLC - Defense World
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences - The Manila Times
Oculis Holding AG to Present Innovative Late-Stage Pipeline at Major Ophthalmology Conferences in May 2025 - Nasdaq
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences - GlobeNewswire Inc.
Oculis Updates Share Capital - The Manila Times
Long Term Trading Analysis for (OCSAW) - news.stocktradersdaily.com
(OCS) Trading Advice - news.stocktradersdaily.com
Chardan Capital Reaffirms Buy Rating for Oculis (NASDAQ:OCS) - Defense World
HC Wainwright Increases Oculis (NASDAQ:OCS) Price Target to $32.00 - Defense World
Oculis (NASDAQ:OCS) Shares Gap Up Following Analyst Upgrade - Defense World
Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award - The Manila Times
Stifel maintains Buy rating, $35 target on Oculis shares By Investing.com - Investing.com South Africa
Stifel maintains Buy rating, $35 target on Oculis shares - Investing.com
Oculis Holding AG Unveils Key Clinical Updates and Future Outlook at R&D Day - TipRanks
Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets - The Manila Times
Oculis completes enrolment in trials for diabetic macular oedema eye drops - Yahoo
Oculis completes enrollment for pivotal DME treatment trials By Investing.com - Investing.com South Africa
Oculis Completes Enrollment in Late-Stage Diabetic Macular Edema Trials - marketscreener.com
Oculis completes enrollment for pivotal DME treatment trials - Investing.com
Oculis Wraps Up Patient Enrollment in Late-stage Studies of Topical Eye Drug - MarketScreener
Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema - The Manila Times
REG-Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema - TradingView
(OCS) Trading Signals - news.stocktradersdaily.com
A First Look At Oculis Holding AG: Revenues Still Several Years Away (NASDAQ:OCS) - Seeking Alpha
Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond - The Manila Times
Oculis Holding AG (NASDAQ:OCS) Short Interest Update - Defense World
Oculis Holding AG (NASDAQ:OCS) Short Interest Down 14.1% in February - Defense World
Oculis' Insider Moves: A Glimpse into the Company's Future? - AInvest
Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities - MarketScreener
Insider Buying: Oculis Holding Independent Director Bought CHF326k Of Shares - simplywall.st
Lionel Carnot Spends CHF326k On Oculis Holding Stock - Yahoo
Equities Analysts Set Expectations for Oculis Q1 Earnings - The AM Reporter
HC Wainwright Comments on Oculis’ Q1 Earnings (NASDAQ:OCS) - Defense World
Robert W. Baird Boosts Oculis (NASDAQ:OCS) Price Target to $41.00 - Defense World
HC Wainwright Lowers Oculis (NASDAQ:OCS) Price Target to $29.00 - Defense World
Oculis (NASDAQ:OCS) Sees Strong Trading Volume After Analyst Upgrade - Defense World
Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update - Informazione.it
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - Marketscreener.com
(OCS) Investment Analysis - Stock Traders Daily
Oculis Holding AG (OCS) Reports Q4 Loss, Misses Revenue Estimates - MSN
Stifel maintains Buy on Oculis shares, price target at $35 By Investing.com - Investing.com Australia
H.C. Wainwright cuts Oculis stock target to $29, keeps Buy rating - Investing.com Australia
H.C. Wainwright cuts Oculis stock target to $29, keeps Buy rating By Investing.com - Investing.com South Africa
Oculis Holding AG Faces Heightened Cybersecurity Risks Amid Geopolitical Tensions - TipRanks
Oculis price target raised to $32 from $31 at BofA - TipRanks
Oculis (NASDAQ:OCS) Shares Gap Down Following Weak Earnings - Defense World
Oculis Holding AG Reports 2024 Financial Results - TipRanks
Oculis Reports 2024 Fourth Quarter Net Loss, Completes $100 Million Equity Financing to Support Pipeline - Vision Monday
Oculis Holding Ag Azioni (OCS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
3.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):